nach oben

Archives of Gynecology and Obstetrics

Erschienen in:

01.04.2014 | Review

Chlamydia trachomatis infection: implications for HPV status and cervical cancer

verfasst von: Jani Silva, Fátima Cerqueira, Rui Medeiros

Erschienen in: Archives of Gynecology and Obstetrics | Ausgabe 4/2014

Einloggen, um Zugang zu erhalten

Abstract

Genital Chlamydia trachomatis (CT) infections have been identified as a major health problem concern. CT is associated with adverse effect on women reproduction and also associated with cervical hypertrophy and induction of squamous metaplasia, providing a possible relationship with human papillomavirus (HPV) infection. Infection by high-risk HPV types is crucial to the pathogenesis of invasive cervical cancer (ICC), but other co-variants/cofactors must be present for the development of malignancy. CT biological effect may damage the mucosal barrier, improving HPV infection, or may interfere in immune response and viral clearance supporting the persistence of HPV infection. Moreover, CT-related chronic cervical inflammation, decrease of lower genital tract antigen-presenting cells, inhibition of cell-mediated immunity, and anti-apoptotic capacity may influence the natural history of HPV infection, namely persistence progression or resolution. Although several epidemiological studies have stated a positive association involving CT and HPV-related cervical neoplastic lesions and/or cervical cancer (CC), the specific role of this bacterium in the pathogenesis of cervical neoplasia has not been completely clarified. The present review summarizes several studies on CT role in cervical cancer and suggests future research directions on HPV and CT interaction.

WHO (1999) Estimated new cases of chlamydial infections among adults

ECDC (2011) Sexually transmitted infections in Europe, 1990–2009. ECDC, Stockholm

Paavonen J (2012) Chlamydia trachomatis infections of the female genital tract: state of the art. Ann Med 44(1):18–28. doi:10.3109/07853890.2010.546365 CrossRefPubMed

Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN. Int J Cancer 127(12):2893–2917. doi:10.1002/ijc.25516 CrossRefPubMed

Simonetti AC, Melo JH, de Souza PR, Bruneska D, de Lima Filho JL (2009) Immunological’s host profile for HPV and Chlamydia trachomatis, a cervical cancer cofactor. Microbes Infect 11(4):435–442. doi:10.1016/j.micinf.2009.01.004 CrossRefPubMed

Paba P, Bonifacio D, Di Bonito L, Ombres D, Favalli C, Syrjanen K, Ciotti M (2008) Co-expression of HSV2 and Chlamydia trachomatis in HPV-positive cervical cancer and cervical intraepithelial neoplasia lesions is associated with aberrations in key intracellular pathways. Intervirology 51(4):230–234. doi:10.1159/000156481 CrossRefPubMed

Koutsky LA, Holmes KK, Critchlow CW, Stevens CE, Paavonen J, Beckmann AM, DeRouen TA, Galloway DA, Vernon D, Kiviat NB (1992) A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection. N Eng J Med 327(18):1272–1278. doi:10.1056/NEJM199210293271804 CrossRef

Smith JS, Herrero R, Bosetti C, Munoz N, Bosch FX, Eluf-Neto J, Castellsague X, Meijer CJ, Van den Brule AJ, Franceschi S, Ashley R (2002) Herpes simplex virus-2 as a human papillomavirus cofactor in the etiology of invasive cervical cancer. J Natl Cancer Inst 94(21):1604–1613. doi:10.1093/jnci/94.21.1604 CrossRefPubMed

Gillet E, Meys JF, Verstraelen H, Verhelst R, De Sutter P, Temmerman M, Vanden Broeck D (2012) Association between bacterial vaginosis and cervical intraepithelial neoplasia: systematic review and meta-analysis. PLoS One 7(10):e45201. doi:10.1371/journal.pone.0045201 PubMedCentralCrossRefPubMed

10.

Silins I, Ryd W, Stre A, Wadell G, Tornberg S, Hansson BG, Wang X, Arnheim L, Dahl V, Bremell D, Persson K, Dillner J, Ryleer E (2005) Chlamydia trachomatis infection and persistence of human papillomavirus. Int J Cancer 116(1):110–115. doi:10.1002/ijc.20970 CrossRefPubMed

11.

Mylonas I (2012) Female genital Chlamydia trachomatis infection: where are we heading? Arch Gynecol Obstet 285(5):1271–1285. doi:10.1007/s00404-012-2240-7 CrossRefPubMed

12.

van de Laar MJ, Morre SA (2007) Chlamydia: a major challenge for public health. Euro Surveill 12(10):E1–E2PubMed

13.

Markowska J, Fischer N, Filas V, Fischer Z, Breborowicz J, Markowski M (1999) The role of Chlamydia trachomatis infection in cervical cancer development. Eur J Gynaecol Oncol 20(2):144–146PubMed

14.

Markowska J, Fischer N, Fischer Z, Warchol JB (2002) Chlamydia trachomatis infection in women with CIN and invasive uterine cervix cancer. Significance of hormonal status. Eur J Gynaecol Oncol 23(6):511–513PubMed

15.

Zenilman JM (2001) Chlamydia and cervical cancer: a real association? JAMA 285(1):81–83. doi:10.1001/jama.285.1.81 CrossRefPubMed

16.

Lu H, Ouyang W, Huang C (2006) Inflammation, a key event in cancer development. Mol Cancer Res 4(4):221–233. doi:10.1158/1541-7786.MCR-05-0261 CrossRefPubMed

17.

Multhoff G, Molls M, Radons J (2011) Chronic inflammation in cancer development. Front Immunol 2:98. doi:10.3389/fimmu.2011.00098 PubMedCentralPubMed

18.

Matos A, Moutinho J, Pinto D, Medeiros R (2005) The influence of smoking and other cofactors on the time to onset to cervical cancer in a southern European population. Eur J Cancer Prev 14(5):485–491 (pii): 00008469-200510000-00007CrossRefPubMed

19.

Silva J, Cerqueira F, Ribeiro J, Sousa H, Osorio T, Medeiros R (2013) Is Chlamydia trachomatis related to human papillomavirus infection in young women of southern European population? A self-sampling study. Arch Gynecol Obstet. doi:10.1007/s00404-013-2771-6

20.

Al-Daraji WI, Smith JH (2009) Infection and cervical neoplasia: facts and fiction. Int J Clin Exp Pathol 2(1):48–64 PMC2491386PubMedCentralPubMed

21.

Silva J, Ribeiro J, Sousa H, Cerqueira F, Teixeira AL, Baldaque I, Osorio T, Medeiros R (2011) Oncogenic HPV types infection in adolescents and university women from North Portugal: from self-sampling to cancer prevention. J Oncol 2011:953469. doi:10.1155/2011/953469 PubMedCentralCrossRefPubMed

22.

Pista A, de Oliveira CF, Cunha MJ, Paixao MT, Real O (2012) Risk factors for human papillomavirus infection among women in Portugal: the CLEOPATRE Portugal study. Int J Gynaecol Obstet 118(2):112–116. doi:10.1016/j.ijgo.2012.03.028 CrossRefPubMed

23.

de Sanjose S, Diaz M, Castellsague X, Clifford G, Bruni L, Munoz N, Bosch FX (2007) Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect Dis 7(7):453–459. doi:10.1016/S1473-3099(07)70158-5 CrossRefPubMed

24.

Franco EL, Duarte-Franco E, Ferenczy A (2001) Cervical cancer: epidemiology, prevention and the role of human papillomavirus infection. CMAJ 164(7):1017–1025PubMedCentralPubMed

25.

Castle PE, Giuliano AR (2003) Chapter 4: genital tract infections, cervical inflammation, and antioxidant nutrients––assessing their roles as human papillomavirus cofactors. J Natl Cancer Inst Monogr 31:29–34CrossRefPubMed

26.

Hawes SE, Kiviat NB (2002) Are genital infections and inflammation cofactors in the pathogenesis of invasive cervical cancer? J Natl Cancer Inst 94(21):1592–1593. doi:10.1093/jnci/94.21.1592 CrossRefPubMed

27.

Samoff E, Koumans EH, Markowitz LE, Sternberg M, Sawyer MK, Swan D, Papp JR, Black CM, Unger ER (2005) Association of Chlamydia trachomatis with persistence of high-risk types of human papillomavirus in a cohort of female adolescents. Am J Epidemiol 162(7):668–675. doi:10.1093/aje/kwi262 CrossRefPubMed

28.

Beatty WL, Morrison RP, Byrne GI (1994) Persistent Chlamydiae: from cell culture to a paradigm for chlamydial pathogenesis. Microbiol Rev 58(4):686–699PubMedCentralPubMed

29.

Castle PE, Hillier SL, Rabe LK, Hildesheim A, Herrero R, Bratti MC, Sherman ME, Burk RD, Rodriguez AC, Alfaro M, Hutchinson ML, Morales J, Schiffman M (2001) An association of cervical inflammation with high-grade cervical neoplasia in women infected with oncogenic human papillomavirus (HPV). Cancer Epidemiol Biomarkers Prev 10(10):1021–1027PubMed

30.

Rasmussen SJ, Eckmann L, Quayle AJ, Shen L, Zhang YX, Anderson DJ, Fierer J, Stephens RS, Kagnoff MF (1997) Secretion of proinflammatory cytokines by epithelial cells in response to Chlamydia infection suggests a central role for epithelial cells in chlamydial pathogenesis. J Clin Investig 99(1):77–87. doi:10.1172/JCI119136 PubMedCentralCrossRefPubMed

31.

de Sá AB, Gomes JP, Viegas S, Ferreira MA, Paulino A, MdA Catry (2002) Genital infection by Chlamydia trachomatis in Lisbon: prevalence and risk markers. Fam Pract 19(4):362–364. doi:10.1093/fampra/19.4.362 CrossRef

32.

Fischer N (2002) Chlamydia trachomatis infection in cervical intraepithelial neoplasia and invasive carcinoma. Eur J Gynaecol Oncol 23(3):247–250 PMID12094964PubMed

33.

Byrne GI, Ojcius DM (2004) Chlamydia and apoptosis: life and death decisions of an intracellular pathogen. Nat Rev Microbiol 2(10):802–808. doi:10.1038/nrmicro1007 CrossRefPubMed

34.

Di Felice V, David S, Cappello F, Farina F, Zummo G (2005) Is chlamydial heat shock protein 60 a risk factor for oncogenesis? Cell Mol Life Sci 62(1):4–9. doi:10.1007/s00018-004-4367-6 CrossRefPubMed

35.

Paavonen J, Karunakaran KP, Noguchi Y, Anttila T, Bloigu A, Dillner J, Hallmans G, Hakulinen T, Jellum E, Koskela P, Lehtinen M, Thoresen S, Lam H, Shen C, Brunham RC (2003) Serum antibody response to the heat shock protein 60 of Chlamydia trachomatis in women with developing cervical cancer. Am J Obstet Gynecol 189(5):1287–1292. doi:10.1067/S0002-9378(03)00755-5 CrossRefPubMed

36.

de Sanjose S, Munoz N, Bosch FX, Reimann K, Pedersen NS, Orfila J, Ascunce N, Gonzalez LC, Tafur L, Gili M et al (1994) Sexually transmitted agents and cervical neoplasia in Colombia and Spain. Int J Cancer 56(3):358–363. doi:10.1002/ijc.2910560311 CrossRefPubMed

37.

Smith JS, Munoz N, Herrero R, Eluf-Neto J, Ngelangel C, Franceschi S, Bosch FX, Walboomers JM, Peeling RW (2002) Evidence for Chlamydia trachomatis as a human papillomavirus cofactor in the etiology of invasive cervical cancer in Brazil and the Philippines. J Infect Dis 185(3):324–331. doi:10.1086/338569 CrossRefPubMed

38.

Matsumoto K, Yasugi T, Oki A, Hoshiai H, Taketani Y, Kawana T, Yoshikawa H (2003) Are smoking and chlamydial infection risk factors for CIN? Different results after adjustment for HPV DNA and antibodies. Br J Cancer 89(5):831–833. doi:10.1038/sj.bjc.6601220 PubMedCentralCrossRefPubMed

39.

Koskela P, Anttila T, Bjorge T, Brunsvig A, Dillner J, Hakama M, Hakulinen T, Jellum E, Lehtinen M, Lenner P, Luostarinen T, Pukkala E, Saikku P, Thoresen S, Youngman L, Paavonen J (2000) Chlamydia trachomatis infection as a risk factor for invasive cervical cancer. Int J Cancer 85(1):35–39. doi:10.1002/(SICI)1097-0215(20000101)85:1<35:AID-IJC6>3.0.CO;2-A CrossRefPubMed

40.

Smith JS, Bosetti C, Munoz N, Herrero R, Bosch FX, Eluf-Neto J, Meijer CJ, Van Den Brule AJ, Franceschi S, Peeling RW, study Imc- c (2004) Chlamydia trachomatis and invasive cervical cancer: a pooled analysis of the IARC multicentric case-control study. Int J Cancer 111(3):431–439. doi:10.1002/ijc.20257 CrossRefPubMed

41.

Naucler P, Chen HC, Persson K, You SL, Hsieh CY, Sun CA, Dillner J, Chen CJ (2007) Seroprevalence of human papillomaviruses and Chlamydia trachomatis and cervical cancer risk: nested case-control study. J Gen Virol 88(Pt 3):814–822. doi:10.1099/vir.0.82503-0 CrossRefPubMed

42.

Anttila T, Saikku P, Koskela P, Bloigu A, Dillner J, Ikaheimo I, Jellum E, Lehtinen M, Lenner P, Hakulinen T, Narvanen A, Pukkala E, Thoresen S, Youngman L, Paavonen J (2001) Serotypes of Chlamydia trachomatis and risk for development of cervical squamous cell carcinoma. JAMA 285(1):47–51. doi:10.1001/jama.285.1.47 CrossRefPubMed

43.

Madeleine MM, Anttila T, Schwartz SM, Saikku P, Leinonen M, Carter JJ, Wurscher M, Johnson LG, Galloway DA, Daling JR (2006) Risk of cervical cancer associated with Chlamydia trachomatis antibodies by histology, HPV type and HPV cofactors. Int J Cancer 120(3):650–655. doi:10.1002/ijc.22325 CrossRef

44.

Jha PK, Beral V, Peto J, Hack S, Hermon C, Deacon J, Mant D, Chilvers C, Vessey MP, Pike MC et al (1993) Antibodies to human papillomavirus and to other genital infectious agents and invasive cervical cancer risk. Lancet 341(8853):1116–1118. doi:10.1016/0140-6736(93)93128-N CrossRefPubMed

45.

Munoz N, Kato I, Bosch FX, Eluf-Neto J, De Sanjose S, Ascunce N, Gili M, Izarzugaza I, Viladiu P, Tormo MJ, Moreo P, Gonzalez LC, Tafur L, Walboomers JM, Shah KV (1996) Risk factors for HPV DNA detection in middle-aged women. Sex Transm Dis 23(6):504–510. doi:PMID8946637 CrossRefPubMed

46.

Quint KD, de Koning MN, Geraets DT, Quint WG, Pirog EC (2009) Comprehensive analysis of human papillomavirus and Chlamydia trachomatis in in situ and invasive cervical adenocarcinoma. Gynecol Oncol 114(3):390–394. doi:10.1016/j.ygyno.2009.05.013 CrossRefPubMed

47.

Luostarinen T, Namujju PB, Merikukka M, Dillner J, Hakulinen T, Koskela P, Paavonen J, Surcel HM, Lehtinen M (2013) Order of HPV/Chlamydia infections and cervical high-grade precancer risk: a case-cohort study. Int J Cancer. doi:10.1002/ijc.28173

48.

Bosch FX, Castellsague X, Munoz N, de Sanjose S, Ghaffari AM, Gonzalez LC, Gili M, Izarzugaza I, Viladiu P, Navarro C, Vergara A, Ascunce N, Guerrero E, Shah KV (1996) Male sexual behavior and human papillomavirus DNA: key risk factors for cervical cancer in Spain. J Natl Cancer Inst 88(15):1060–1067. doi:10.1093/jnci/88.15.1060 CrossRefPubMed

49.

Munoz N, Castellsague X, Bosch FX, Tafur L, de Sanjose S, Aristizabal N, Ghaffari AM, Shah KV (1996) Difficulty in elucidating the male role in cervical cancer in Colombia, a high-risk area for the disease. J Natl Cancer Inst 88(15):1068–1075. doi:10.1093/jnci/88.15.1068 CrossRefPubMed

50.

Safaeian M, Quint K, Schiffman M, Rodriguez AC, Wacholder S, Herrero R, Hildesheim A, Viscidi RP, Quint W, Burk RD (2010) Chlamydia trachomatis and risk of prevalent and incident cervical premalignancy in a population-based cohort. J Natl Cancer Inst 102(23):1794–1804. doi:10.1093/jnci/djq436 PubMedCentralCrossRefPubMed

51.

Yokoyama M, Iwasaka T, Nagata C, Nozawa S, Sekiya S, Hirai Y, Kanazawa K, Sato S, Hoshiai H, Sugase M, Kawana T, Yoshikawa H (2003) Prognostic factors associated with the clinical outcome of cervical intraepithelial neoplasia: a cohort study in Japan. Cancer Lett 192(2):171–179. doi:10.1016/S0304-3835(02)00715-2 CrossRefPubMed

52.

Castle PE, Escoffery C, Schachter J, Rattray C, Schiffman M, Moncada J, Sugai K, Brown C, Cranston B, Hanchard B, Palefsky JM, Burk RD, Hutchinson ML, Strickler HD (2003) Chlamydia trachomatis, herpes simplex virus 2, and human T-cell lymphotrophic virus type 1 are not associated with grade of cervical neoplasia in Jamaican colposcopy patients. Sex Transm Dis 30(7):575–580. doi:10.1097/00007435-200307000-00009 CrossRefPubMed

53.

Ferrera A, Baay MF, Herbrink P, Figueroa M, Velema JP, Melchers WJ (1997) A sero-epidemiological study of the relationship between sexually transmitted agents and cervical cancer in Honduras. Int J Cancer 73(6):781–785. doi:10.1002/(SICI)1097-0215(19971210)73:6<781:AID-IJC1>3.0.CO;2-Z CrossRefPubMed

54.

Lehtinen M, Dillner J, Knekt P, Luostarinen T, Aromaa A, Kirnbauer R, Koskela P, Paavonen J, Peto R, Schiller JT, Hakama M (1996) Serologically diagnosed infection with human papillomavirus type 16 and risk for subsequent development of cervical carcinoma: nested case-control study. BMJ 312(7030):537–539 PMC2350335PubMedCentralCrossRefPubMed

55.

Becker TM, Wheeler CM, McGough NS, Parmenter CA, Jordan SW, Stidley CA, McPherson RS, Dorin MH (1994) Sexually transmitted diseases and other risk factors for cervical dysplasia among southwestern Hispanic and non-Hispanic white women. JAMA 271(15):1181–1188. doi:10.1001/jama.1994.03510390051029 CrossRefPubMed

56.

Wallin KL, Wiklund F, Luostarinen T, Angstrom T, Anttila T, Bergman F, Hallmans G, Ikaheimo I, Koskela P, Lehtinen M, Stendahl U, Paavonen J, Dillner J (2002) A population-based prospective study of Chlamydia trachomatis infection and cervical carcinoma. Int J Cancer 101(4):371–374. doi:10.1002/ijc.10639 CrossRefPubMed

57.

Golijow CD, Abba MC, Mouron SA, Laguens RM, Dulout FN, Smith JS (2005) Chlamydia trachomatis and human papillomavirus infections in cervical disease in Argentine women. Gynecol Oncol 96(1):181–186. doi:10.1016/j.ygyno.2004.09.037 CrossRefPubMed

58.

Lehtinen M, Ault KA, Lyytikainen E, Dillner J, Garland SM, Ferris DG, Koutsky LA, Sings HL, Lu S, Haupt RM, Paavonen J, Future I, Group IIS (2011) Chlamydia trachomatis infection and risk of cervical intraepithelial neoplasia. Sex Transm Infect 87(5):372–376. doi:10.1136/sti.2010.044354 PubMedCentralCrossRefPubMed

59.

Giuliano AR, Papenfuss M, Abrahamsen M, Denman C, de Zapien JG, Henze JL, Ortega L, Brown de Galaz EM, Stephan J, Feng J, Baldwin S, Garcia F, Hatch K (2001) Human papillomavirus infection at the United States–Mexico border: implications for cervical cancer prevention and control. Cancer Epidemiol Biomarkers Prev 10(11):1129–1136PubMed

60.

Giuliano AR, Papenfuss M, Abrahamsen M, Inserra P (2002) Differences in factors associated with oncogenic and nononcogenic human papillomavirus infection at the United States–Mexico border. Cancer Epidemiol Biomarkers Prev 11(9):930–934PubMed

61.

Verteramo R, Pierangeli A, Mancini E, Calzolari E, Bucci M, Osborn J, Nicosia R, Chiarini F, Antonelli G, Degener AM (2009) Human Papillomaviruses and genital co-infections in gynaecological outpatients. BMC Infect Dis 9:16. doi:10.1186/1471-2334-9-16 PubMedCentralCrossRefPubMed

62.

Gopalkrishna V, Aggarwal N, Malhotra VL, Koranne RV, Mohan VP, Mittal A, Das BC (2000) Chlamydia trachomatis and human papillomavirus infection in Indian women with sexually transmitted diseases and cervical precancerous and cancerous lesions. Clin Microbiol Infec 6(2):88–93. doi:10.1046/j.1469-0691.2000.00024.x CrossRef

63.

Finan RR, Tamim H, Almawi WY (2002) Identification of Chlamydia trachomatis DNA in human papillomavirus (HPV) positive women with normal and abnormal cytology. Arch Gynecol Obstet 266(3):168–171. doi:10.1007/s00404-001-0261-8 CrossRefPubMed

64.

Tamim H, Finan RR, Sharida HE, Rashid M, Almawi WY (2002) Cervicovaginal coinfections with human papillomavirus and Chlamydia trachomatis. Diagn Microbiol Infect Dis 43(4):277–281. doi:10.1016/S0732-8893(02)00403-0 CrossRefPubMed

65.

Lehmann M, Groh A, Rodel J, Nindl I, Straube E (1999) Detection of Chlamydia trachomatis DNA in cervical samples with regard to infection by human papillomavirus. J Infect 38(1):12–17. doi:10.1016/S0163-4453(99)90021-X CrossRefPubMed

66.

Molano M, Weiderpass E, Posso H, Morre SA, Ronderos M, Franceschi S, Arslan A, Meijer CJ, Munoz N, van den Brule AJ, Group HPVS (2003) Prevalence and determinants of Chlamydia trachomatis infections in women from Bogota, Colombia. Sex Transm Infect 79(6):474–478. doi:10.1136/sti.79.6.474 PubMedCentralCrossRefPubMed

67.

da Silva CS, Adad SJ, Hazarabedian de Souza MA, Macedo Barcelos AC, Sarreta Terra AP, Murta EF (2004) Increased frequency of bacterial vaginosis and Chlamydia trachomatis in pregnant women with human papillomavirus infection. Gynecol Obstet Invest 58(4):189–193. doi:10.1159/000079822 CrossRefPubMed

68.

Giuliano AR, Papenfuss M, De Galaz EM, Feng J, Abrahamsen M, Denman C, De Zapien JG, Navarro Henze JL, Garcia F, Hatch K (2004) Risk factors for squamous intraepithelial lesions (SIL) of the cervix among women residing at the US–Mexico border. Int J Cancer 109(1):112–118. doi:10.1002/ijc.11656 CrossRefPubMed

69.

de Paula FDF, Fernandes AP, BBd Carmo, Vieira DCD, Dutra MS, CGMd Santos, MdCM Souza, Andrade TCA, Vago AR, Fernandes PÁ (2007) Molecular detection of Chlamydia trachomatis and HPV infections in cervical samples with normal and abnormal cytopathological findings. Diagn Cytopathol 35(4):198–202. doi:10.1002/dc.20629 CrossRefPubMed

70.

Bhatla N, Puri K, Joseph E, Kriplani A, Iyer VK, Sreenivas V (2013) Association of Chlamydia trachomatis infection with human papillomavirus (HPV) & cervical intraepithelial neoplasia - A pilot study. Indian J Med Res 137(3):533–539PubMedCentralPubMed

71.

GLOBOCAN Cancer Incidence and Mortality Worldwide (2008). http://globocan.iarc.fr/

Titel: Chlamydia trachomatis infection: implications for HPV status and cervical cancer
verfasst von: Jani Silva
Fátima Cerqueira
Rui Medeiros
Publikationsdatum: 01.04.2014
Verlag: Springer Berlin Heidelberg
Erschienen in: Archives of Gynecology and Obstetrics / Ausgabe 4/2014
Print ISSN: 0932-0067
Elektronische ISSN: 1432-0711
DOI: https://doi.org/10.1007/s00404-013-3122-3

Neu im Fachgebiet Gynäkologie und Geburtshilfe

23.04.2024 | Medikamente in Schwangerschaft und Stillzeit | Nachrichten

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen

Springer Medizin

Chlamydia trachomatis infection: implications for HPV status and cervical cancer

Abstract

Neu im Fachgebiet Gynäkologie und Geburtshilfe

ICI-Therapie in der Schwangerschaft wird gut toleriert

Weniger postpartale Depressionen nach Esketamin-Einmalgabe

Bei RSV-Impfung vor 60. Lebensjahr über Off-Label-Gebrauch aufklären!

Harnwegsinfektprophylaxe: Es geht auch ohne Antibiotika

Update Gynäkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2014

The rs266729 single-nucleotide polymorphism in the adiponectin gene shows association with gestational diabetes

The impact of the body mass index (BMI) on laparoscopic hysterectomy for benign disease

Sublingual misoprostol versus intravenous oxytocin in prevention of post-partum hemorrhage

Polypoid endometriosis of the cervix: a case report and review of the literature

Assessment of ovarian stromal blood flow after metformin treatment in women with polycystic ovary syndrome

The role of a personalized dietary intervention in managing gestational weight gain: a prospective, controlled study in a low-risk antenatal population

Neu im Fachgebiet Gynäkologie und Geburtshilfe

ICI-Therapie in der Schwangerschaft wird gut toleriert

Weniger postpartale Depressionen nach Esketamin-Einmalgabe

Bei RSV-Impfung vor 60. Lebensjahr über Off-Label-Gebrauch aufklären!

Harnwegsinfektprophylaxe: Es geht auch ohne Antibiotika

Update Gynäkologie